| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_827661dc4189cda185ca53beebcfb05b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-524 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-1044
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y203-02013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6889
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6855
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2021-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af50089e79c85148325c403b6a6ddf4c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16a55f97c4a136fc2ad3cb5c97bcd079
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_617a040a24e2fa975182b919a8bb270e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1386599e9380e7062b8191c1efdb241
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_996e29bf75c0a22aca4bd04eb9ad3bfb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25b5eeebeee76be967ca405a54244aa6 |
| publicationDate |
2022-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022084560-A1 |
| titleOfInvention |
Means and methods for producing antibody-linker conjugates |
| abstract |
The present invention relates to a method for generating an antibody-payload conjugate by means of a microbial transglutaminase (MTG). The method comprises a step of conjugating a linker comprising the structure (shown in N -> C direction) (Sp 1 )-RK-(Sp 2 )-B-(Sp 3 ) or (Sp 1 )- B-(Sp 2 )-RK-(Sp 3 ) to a Gin residue comprised in an antibody, wherein (Sp 1 ) is a chemical spacer or is absent; (Sp 2 ) is a chemical spacer or is absent; (Sp 3 ) is a chemical spacer or is absent; R is arginine or an arginine derivative or an arginine mimetic; K is lysine or a lysine derivative or a lysine mimetic; B is a linking moiety or a payload; and wherein the linker is conjugated to the Gln residue comprised in the antibody via a primary amine comprised in the side chain of the lysine residue, the lysine derivative or the lysine mimetic. Further, the invention relates to antibody-linker conjugates, antibody-drug conjugates and linker constructs comprising an RK motif. |
| priorityDate |
2020-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |